Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Brand

Showing results (11-20 of 124) with videos related to

Pageof 13
Sort By:
Pflugers Archiv : European Journal of Physiology|November 26, 2014
Salt controls endothelial and vascular phenotypeKristina Kusche-Vihrog, Boris Schmitz, Eva Brand
Biochimica Et Biophysica Acta|June 8, 2014
Aldosterone signaling and soluble adenylyl cyclase-a nexus for the kidney and vascular endotheliumBoris Schmitz, Stefan-Martin Brand, Eva Brand
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 1, 2025
Progress and Challenges in the Treatment of Fabry DiseaseMalte Lenders, Elise Raphaela Menke, Eva Brand
Molecular Genetics and Metabolism|September 5, 2020
Detailed epitope mapping of neutralizing anti-drug antibodies against recombinant α-galactosidase A in patients with Fabry diseaseDavid Scharnetzki, Franciska Stappers, Malte Lenders, et al.
Molecular Therapy. Methods & Clinical Development|August 22, 2022
Pre-existing anti-drug antibodies in Fabry disease show less affinity for pegunigalsidase alfaMalte Lenders, Solvey Pollmann, Melina Terlinden, et al.
Orphanet Journal of Rare Diseases|October 1, 2018
Neutralizing anti-drug antibodies in Fabry disease have no obvious clinical impact?Malte Lenders, Boris Schmitz, Stefan-Martin Brand, et al.
Frontiers in Immunology|December 17, 2021
Endothelial Dysfunction in Fabry Disease Is Related to Glycocalyx DegradationSolvey Pollmann, David Scharnetzki, Dominique Manikowski, et al.
Frontiers in Immunology|October 11, 2023
Characterization of pre-existing anti-PEG and anti-AGAL antibodies towards PRX-102 in patients with Fabry diseaseMalte Lenders, Lina Marleen Feidicker, Stefan-Martin Brand, et al.
Bioprocess and Biosystems Engineering|November 27, 2012
Enhanced plasmid production in miniaturized high-cell-density cultures of Escherichia coli supported with perfluorinated oxygen carrierMaciej Pilarek, Eva Brand, Friederike Hillig, et al.
Frontiers in Immunology|January 29, 2026
A rapid method to reduce drug interferences for antibody measurements in pegunigalsidase alfa-treated patients with Fabry diseaseMalte Lenders, Elisa Rudolph, Michael Rudnicki, et al.
Pageof 13

Showing results (11-20 of 124) with videos related to

Sort By:
Pageof 13
Pflugers Archiv : European Journal of Physiology|November 26, 2014
Salt controls endothelial and vascular phenotypeKristina Kusche-Vihrog, Boris Schmitz, Eva Brand
Biochimica Et Biophysica Acta|June 8, 2014
Aldosterone signaling and soluble adenylyl cyclase-a nexus for the kidney and vascular endotheliumBoris Schmitz, Stefan-Martin Brand, Eva Brand
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 1, 2025
Progress and Challenges in the Treatment of Fabry DiseaseMalte Lenders, Elise Raphaela Menke, Eva Brand
Molecular Genetics and Metabolism|September 5, 2020
Detailed epitope mapping of neutralizing anti-drug antibodies against recombinant α-galactosidase A in patients with Fabry diseaseDavid Scharnetzki, Franciska Stappers, Malte Lenders, et al.
Molecular Therapy. Methods & Clinical Development|August 22, 2022
Pre-existing anti-drug antibodies in Fabry disease show less affinity for pegunigalsidase alfaMalte Lenders, Solvey Pollmann, Melina Terlinden, et al.
Orphanet Journal of Rare Diseases|October 1, 2018
Neutralizing anti-drug antibodies in Fabry disease have no obvious clinical impact?Malte Lenders, Boris Schmitz, Stefan-Martin Brand, et al.
Frontiers in Immunology|December 17, 2021
Endothelial Dysfunction in Fabry Disease Is Related to Glycocalyx DegradationSolvey Pollmann, David Scharnetzki, Dominique Manikowski, et al.
Frontiers in Immunology|October 11, 2023
Characterization of pre-existing anti-PEG and anti-AGAL antibodies towards PRX-102 in patients with Fabry diseaseMalte Lenders, Lina Marleen Feidicker, Stefan-Martin Brand, et al.
Bioprocess and Biosystems Engineering|November 27, 2012
Enhanced plasmid production in miniaturized high-cell-density cultures of Escherichia coli supported with perfluorinated oxygen carrierMaciej Pilarek, Eva Brand, Friederike Hillig, et al.
Frontiers in Immunology|January 29, 2026
A rapid method to reduce drug interferences for antibody measurements in pegunigalsidase alfa-treated patients with Fabry diseaseMalte Lenders, Elisa Rudolph, Michael Rudnicki, et al.
Pageof 13